NAS:SRPT (USA) Also trade in: Germany UK

Sarepta Therapeutics Inc

$ 127.26 7.69 (6.43%)
Volume: 1,130,422 Avg Vol (1m): 909,833
Market Cap $: 9.14 Bil Enterprise Value $: 8.22 Bil
P/E (TTM): 0.00 P/B: 6.55
Earnings Power Value -1505.25
Net Current Asset Value 14.72
Tangible Book 18.64
Projected FCF -17.81
Median P/S Value 121.29
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 3.16
Cash-To-Debt ranked lower than
71.15% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
SRPT: 3.16
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.91, Med: 136.9, Max: 10000
Current: 3.16
1.91
10000
Equity-to-Asset 0.69
Equity-to-Asset ranked lower than
63.43% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
SRPT: 0.69
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.09, Med: 0.84, Max: 0.98
Current: 0.69
-0.09
0.98
Debt-to-Equity 0.32
Debt-to-Equity ranked lower than
72.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
SRPT: 0.32
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.68, Med: 0.09, Max: 2.07
Current: 0.32
-0.68
2.07
Debt-to-EBITDA -1.16
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
SRPT: -1.16
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -11.93, Med: -0.08, Max: -0.02
Current: -1.16
-11.93
-0.02
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.93
DISTRESS
GREY
SAFE
Beneish M-Score -0.34
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -148.1%
WACC 11.61%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -121.04
Operating Margin ranked higher than
54.67% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
SRPT: -121.04
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -17572.55, Med: -102.85, Max: -71.16
Current: -121.04
-17572.55
-71.16
Net Margin % -124.66
Net Margin ranked higher than
52.02% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
SRPT: -124.66
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -17560.26, Med: -233.99, Max: -4.93
Current: -124.66
-17560.26
-4.93
ROE % -44.83
ROE ranked higher than
56.42% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
SRPT: -44.83
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -309.2, Med: -80.43, Max: -9
Current: -44.83
-309.2
-9
ROA % -27.48
ROA ranked higher than
61.81% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
SRPT: -27.48
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -93.53, Med: -52.56, Max: -4.62
Current: -27.48
-93.53
-4.62
ROC (Joel Greenblatt) % -222.18
ROC (Joel Greenblatt) ranked higher than
68.63% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
SRPT: -222.18
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -978.9, Med: -512.65, Max: -59.99
Current: -222.18
-978.9
-59.99
3-Year Total Revenue Growth Rate 521.70
3-Year Revenue Growth Rate ranked higher than
95.55% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
SRPT: 433.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -73.3, Med: 10.45, Max: 433.1
Current: 433.1
-73.3
433.1
3-Year Total EBITDA Growth Rate -15.10
3-Year EBITDA Growth Rate ranked higher than
88.78% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
SRPT: 0.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -61.7, Med: -2.3, Max: 42.6
Current: 0.9
-61.7
42.6
3-Year EPS w/o NRI Growth Rate -1.60
3-Year EPS w/o NRI Growth Rate ranked higher than
82.18% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
SRPT: -1.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -213.5, Med: -0.2, Max: 62.2
Current: -1.6
-213.5
62.2

» SRPT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SRPT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:SAGE NAS:IONS NAS:JAZZ HKSE:06160 NAS:TECH NAS:ALNY SZSE:000661 NAS:NBIX NAS:MRNA NAS:BLUE NAS:SGEN OCSE:GEN HKSE:02269 XAMS:GLPG NAS:EXEL HKSE:01177 NAS:ASND NAS:ARRY TSE:4587 NAS:NKTR
Traded in other countries AB3A.Germany 0L35.UK
Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Ratios

Current vs industry vs history
PB Ratio 6.55
PB Ratio ranked lower than
84.62% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
SRPT: 6.55
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2, Med: 6.12, Max: 238.78
Current: 6.55
2
238.78
PS Ratio 25.93
PS Ratio ranked lower than
69.70% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
SRPT: 25.93
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.56, Med: 25.53, Max: 39930
Current: 25.93
1.56
39930
EV-to-EBIT -21.53
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
SRPT: -21.53
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -82.8, Med: -7.25, Max: -1.1
Current: -21.53
-82.8
-1.1
EV-to-EBITDA -22.49
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
SRPT: -22.49
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -101.3, Med: -7.65, Max: -1.1
Current: -22.49
-101.3
-1.1
EV-to-Revenue 25.42
EV-to-Revenue ranked lower than
65.24% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
SRPT: 25.42
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.8, Med: 24, Max: 58632.1
Current: 25.42
0.8
58632.1
Current Ratio 12.17
Current Ratio ranked higher than
78.49% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
SRPT: 12.17
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.76, Med: 7.53, Max: 36.25
Current: 12.17
0.76
36.25
Quick Ratio 11.15
Quick Ratio ranked higher than
76.91% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
SRPT: 11.15
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.76, Med: 7.5, Max: 36.25
Current: 11.15
0.76
36.25
Days Inventory 1.00
Days Inventory ranked higher than
98.34% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
SRPT: 1
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 1, Med: 2393.08, Max: 23152.2
Current: 1
1
23152.2
Days Sales Outstanding 56.11
Days Sales Outstanding ranked higher than
50.90% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
SRPT: 56.11
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 28.22, Med: 62.95, Max: 1158.5
Current: 56.11
28.22
1158.5
Days Payable 237.80
Days Payable ranked higher than
87.13% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
SRPT: 237.8
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 237.8, Med: 420.3, Max: 107295.54
Current: 237.8
237.8
107295.54

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -13.60
3-Year Share Buyback Rate ranked lower than
56.24% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
SRPT: -13.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -27.6, Med: -19.2, Max: -12.9
Current: -13.6
-27.6
-12.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.61
Price-to-Tangible-Book ranked lower than
79.08% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
SRPT: 6.61
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.41, Med: 5.08, Max: 395
Current: 6.61
2.41
395
Price-to-Median-PS-Value 1.02
Price-to-Median-PS-Value ranked lower than
73.01% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
SRPT: 1.02
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.08, Med: 2.82, Max: 1070.33
Current: 1.02
0.08
1070.33
Earnings Yield (Joel Greenblatt) % -4.66
Earnings Yield (Greenblatt) ranked higher than
72.99% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
SRPT: -4.66
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -94.6, Med: -13.85, Max: -1.2
Current: -4.66
-94.6
-1.2

More Statistics

Revenue (TTM) (Mil) $ 323.44
EPS (TTM) $ -5.94
Beta 1.63
Volatility % 66.02
52-Week Range $ 94.66 - 176.5
Shares Outstanding (Mil) 71.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N